GlycoMimetics to Present at Jefferies 2021 Virtual Healthcare Conference

Rhea-AI Summary

GlycoMimetics, Inc. (Nasdaq: GLYC) announces that CEO Rachel King will present a company overview at the Jefferies 2021 Virtual Healthcare Conference on June 3, 2021, from 2:30 to 2:55 p.m. The company focuses on developing glycobiology-based therapies for acute myeloid leukemia (AML) and breast cancer. Its leading drug candidate, uproleselan, has received Breakthrough Therapy Designation in the U.S. and China and is being evaluated in a Phase 3 trial for relapsed/refractory AML. More details are available on their website.

GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that Chief Executive Officer Rachel King will provide a company overview at the Jefferies 2021 Virtual Healthcare Conference. Ms. King’s presentation will take place from 2:30 to 2:55 p.m. on June 3, 2021. More information is available in the Investors section of the GlycoMimetics website.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and breast cancer, and other inflammatory diseases with high unmet need. Our science is based on an understanding of the role that carbohydrates play on the surface of every living cell and applying our specialized chemistry platform to discover small molecule drugs, known as glycomimetics, that alter these carbohydrate-mediated pathways in a variety of disease states, including signaling in cancer and inflammation. As a leader in this space, we are leveraging this unique targeted approach to advance our pipeline of wholly owned drug candidates, with the goal of developing transformative therapies for serious diseases. Our leading drug candidate, uproleselan, has received Breakthrough Therapy Designation in the U.S. and China and is undergoing evaluation across a range of patient populations, including a Phase 3 trial in relapsed/refractory AML. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005938/en/

FAQ

What is GlycoMimetics' main focus as of June 2021?

GlycoMimetics focuses on discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and breast cancer.

When will Rachel King speak at the Jefferies 2021 Virtual Healthcare Conference?

Rachel King will present at the Jefferies 2021 Virtual Healthcare Conference on June 3, 2021, from 2:30 to 2:55 p.m.

What is the status of GlycoMimetics' leading drug candidate, uproleselan?

Uproleselan has received Breakthrough Therapy Designation in the U.S. and China and is currently undergoing evaluation in a Phase 3 trial for relapsed/refractory AML.

Where is GlycoMimetics located?

GlycoMimetics is located in Rockville, MD, in the BioHealth Capital Region.

How can I find more information about GlycoMimetics?

More information about GlycoMimetics can be found on their website at www.glycomimetics.com.